Tumour-Induced Osteomalacia Market, Global Outlook and Forecast 2022-2028

July 2024 | 65 pages | ID: T7FEA3C24CE2EN
Market Monitor Global

Abstracts

Tumour-induced osteomalacia or oncogenic osteomalacia is a rare paraneoplastic syndrome of bone which consist of osteomalacia or rickets induced by phosphaturic mesenchymal tumour (PMT). Tumour-induced osteomalacia diagnosed with an elevated level of blood fibroblast growth factor 23 (FGF23), phosphate and vitamin D-regulating hormone.

This report contains market size and forecasts of Tumour-Induced Osteomalacia in Global, including the following market information:

Global Tumour-Induced Osteomalacia Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Tumour-Induced Osteomalacia market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Drugs Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Tumour-Induced Osteomalacia include Kyowa Kirin, Taizhou Hisound Pharmaceutical, Zhejiang Garden Biochemical High-tech, Kingdomway Nutrition, Amgen, Forgo Pharmaceuticals, Abbott, Solvay and GE Healthcare and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Tumour-Induced Osteomalacia companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Tumour-Induced Osteomalacia Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Tumour-Induced Osteomalacia Market Segment Percentages, by Type, 2021 (%)

• Drugs
• Supplements
• Surgery
• Others

Global Tumour-Induced Osteomalacia Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Tumour-Induced Osteomalacia Market Segment Percentages, by Application, 2021 (%)

• Laboratories
• Bone Scan
• Differential Diagnosis
• Others

Global Tumour-Induced Osteomalacia Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Tumour-Induced Osteomalacia Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Tumour-Induced Osteomalacia revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Tumour-Induced Osteomalacia revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Kyowa Kirin
• Taizhou Hisound Pharmaceutical
• Zhejiang Garden Biochemical High-tech
• Kingdomway Nutrition
• Amgen
• Forgo Pharmaceuticals
• Abbott
• Solvay
• GE Healthcare
• Siemens

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Tumour-Induced Osteomalacia Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Tumour-Induced Osteomalacia Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL TUMOUR-INDUCED OSTEOMALACIA OVERALL MARKET SIZE

2.1 Global Tumour-Induced Osteomalacia Market Size: 2021 VS 2028
2.2 Global Tumour-Induced Osteomalacia Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Tumour-Induced Osteomalacia Players in Global Market
3.2 Top Global Tumour-Induced Osteomalacia Companies Ranked by Revenue
3.3 Global Tumour-Induced Osteomalacia Revenue by Companies
3.4 Top 3 and Top 5 Tumour-Induced Osteomalacia Companies in Global Market, by Revenue in 2021
3.5 Global Companies Tumour-Induced Osteomalacia Product Type
3.6 Tier 1, Tier 2 and Tier 3 Tumour-Induced Osteomalacia Players in Global Market
  3.6.1 List of Global Tier 1 Tumour-Induced Osteomalacia Companies
  3.6.2 List of Global Tier 2 and Tier 3 Tumour-Induced Osteomalacia Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Tumour-Induced Osteomalacia Market Size Markets, 2021 & 2028
  4.1.2 Drugs
  4.1.3 Supplements
  4.1.4 Surgery
  4.1.5 Others
4.2 By Type - Global Tumour-Induced Osteomalacia Revenue & Forecasts
  4.2.1 By Type - Global Tumour-Induced Osteomalacia Revenue, 2017-2022
  4.2.2 By Type - Global Tumour-Induced Osteomalacia Revenue, 2023-2028
  4.2.3 By Type - Global Tumour-Induced Osteomalacia Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Tumour-Induced Osteomalacia Market Size, 2021 & 2028
  5.1.2 Laboratories
  5.1.3 Bone Scan
  5.1.4 Differential Diagnosis
  5.1.5 Others
5.2 By Application - Global Tumour-Induced Osteomalacia Revenue & Forecasts
  5.2.1 By Application - Global Tumour-Induced Osteomalacia Revenue, 2017-2022
  5.2.2 By Application - Global Tumour-Induced Osteomalacia Revenue, 2023-2028
  5.2.3 By Application - Global Tumour-Induced Osteomalacia Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Tumour-Induced Osteomalacia Market Size, 2021 & 2028
6.2 By Region - Global Tumour-Induced Osteomalacia Revenue & Forecasts
  6.2.1 By Region - Global Tumour-Induced Osteomalacia Revenue, 2017-2022
  6.2.2 By Region - Global Tumour-Induced Osteomalacia Revenue, 2023-2028
  6.2.3 By Region - Global Tumour-Induced Osteomalacia Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Tumour-Induced Osteomalacia Revenue, 2017-2028
  6.3.2 US Tumour-Induced Osteomalacia Market Size, 2017-2028
  6.3.3 Canada Tumour-Induced Osteomalacia Market Size, 2017-2028
  6.3.4 Mexico Tumour-Induced Osteomalacia Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Tumour-Induced Osteomalacia Revenue, 2017-2028
  6.4.2 Germany Tumour-Induced Osteomalacia Market Size, 2017-2028
  6.4.3 France Tumour-Induced Osteomalacia Market Size, 2017-2028
  6.4.4 U.K. Tumour-Induced Osteomalacia Market Size, 2017-2028
  6.4.5 Italy Tumour-Induced Osteomalacia Market Size, 2017-2028
  6.4.6 Russia Tumour-Induced Osteomalacia Market Size, 2017-2028
  6.4.7 Nordic Countries Tumour-Induced Osteomalacia Market Size, 2017-2028
  6.4.8 Benelux Tumour-Induced Osteomalacia Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Tumour-Induced Osteomalacia Revenue, 2017-2028
  6.5.2 China Tumour-Induced Osteomalacia Market Size, 2017-2028
  6.5.3 Japan Tumour-Induced Osteomalacia Market Size, 2017-2028
  6.5.4 South Korea Tumour-Induced Osteomalacia Market Size, 2017-2028
  6.5.5 Southeast Asia Tumour-Induced Osteomalacia Market Size, 2017-2028
  6.5.6 India Tumour-Induced Osteomalacia Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Tumour-Induced Osteomalacia Revenue, 2017-2028
  6.6.2 Brazil Tumour-Induced Osteomalacia Market Size, 2017-2028
  6.6.3 Argentina Tumour-Induced Osteomalacia Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Tumour-Induced Osteomalacia Revenue, 2017-2028
  6.7.2 Turkey Tumour-Induced Osteomalacia Market Size, 2017-2028
  6.7.3 Israel Tumour-Induced Osteomalacia Market Size, 2017-2028
  6.7.4 Saudi Arabia Tumour-Induced Osteomalacia Market Size, 2017-2028
  6.7.5 UAE Tumour-Induced Osteomalacia Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Kyowa Kirin
  7.1.1 Kyowa Kirin Corporate Summary
  7.1.2 Kyowa Kirin Business Overview
  7.1.3 Kyowa Kirin Tumour-Induced Osteomalacia Major Product Offerings
  7.1.4 Kyowa Kirin Tumour-Induced Osteomalacia Revenue in Global Market (2017-2022)
  7.1.5 Kyowa Kirin Key News
7.2 Taizhou Hisound Pharmaceutical
  7.2.1 Taizhou Hisound Pharmaceutical Corporate Summary
  7.2.2 Taizhou Hisound Pharmaceutical Business Overview
  7.2.3 Taizhou Hisound Pharmaceutical Tumour-Induced Osteomalacia Major Product Offerings
  7.2.4 Taizhou Hisound Pharmaceutical Tumour-Induced Osteomalacia Revenue in Global Market (2017-2022)
  7.2.5 Taizhou Hisound Pharmaceutical Key News
7.3 Zhejiang Garden Biochemical High-tech
  7.3.1 Zhejiang Garden Biochemical High-tech Corporate Summary
  7.3.2 Zhejiang Garden Biochemical High-tech Business Overview
  7.3.3 Zhejiang Garden Biochemical High-tech Tumour-Induced Osteomalacia Major Product Offerings
  7.3.4 Zhejiang Garden Biochemical High-tech Tumour-Induced Osteomalacia Revenue in Global Market (2017-2022)
  7.3.5 Zhejiang Garden Biochemical High-tech Key News
7.4 Kingdomway Nutrition
  7.4.1 Kingdomway Nutrition Corporate Summary
  7.4.2 Kingdomway Nutrition Business Overview
  7.4.3 Kingdomway Nutrition Tumour-Induced Osteomalacia Major Product Offerings
  7.4.4 Kingdomway Nutrition Tumour-Induced Osteomalacia Revenue in Global Market (2017-2022)
  7.4.5 Kingdomway Nutrition Key News
7.5 Amgen
  7.5.1 Amgen Corporate Summary
  7.5.2 Amgen Business Overview
  7.5.3 Amgen Tumour-Induced Osteomalacia Major Product Offerings
  7.5.4 Amgen Tumour-Induced Osteomalacia Revenue in Global Market (2017-2022)
  7.5.5 Amgen Key News
7.6 Forgo Pharmaceuticals
  7.6.1 Forgo Pharmaceuticals Corporate Summary
  7.6.2 Forgo Pharmaceuticals Business Overview
  7.6.3 Forgo Pharmaceuticals Tumour-Induced Osteomalacia Major Product Offerings
  7.6.4 Forgo Pharmaceuticals Tumour-Induced Osteomalacia Revenue in Global Market (2017-2022)
  7.6.5 Forgo Pharmaceuticals Key News
7.7 Abbott
  7.7.1 Abbott Corporate Summary
  7.7.2 Abbott Business Overview
  7.7.3 Abbott Tumour-Induced Osteomalacia Major Product Offerings
  7.7.4 Abbott Tumour-Induced Osteomalacia Revenue in Global Market (2017-2022)
  7.7.5 Abbott Key News
7.8 Solvay
  7.8.1 Solvay Corporate Summary
  7.8.2 Solvay Business Overview
  7.8.3 Solvay Tumour-Induced Osteomalacia Major Product Offerings
  7.8.4 Solvay Tumour-Induced Osteomalacia Revenue in Global Market (2017-2022)
  7.8.5 Solvay Key News
7.9 GE Healthcare
  7.9.1 GE Healthcare Corporate Summary
  7.9.2 GE Healthcare Business Overview
  7.9.3 GE Healthcare Tumour-Induced Osteomalacia Major Product Offerings
  7.9.4 GE Healthcare Tumour-Induced Osteomalacia Revenue in Global Market (2017-2022)
  7.9.5 GE Healthcare Key News
7.10 Siemens
  7.10.1 Siemens Corporate Summary
  7.10.2 Siemens Business Overview
  7.10.3 Siemens Tumour-Induced Osteomalacia Major Product Offerings
  7.10.4 Siemens Tumour-Induced Osteomalacia Revenue in Global Market (2017-2022)
  7.10.5 Siemens Key News

8 CONCLUSION


9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Tumour-Induced Osteomalacia Market Opportunities & Trends in Global Market
Table 2. Tumour-Induced Osteomalacia Market Drivers in Global Market
Table 3. Tumour-Induced Osteomalacia Market Restraints in Global Market
Table 4. Key Players of Tumour-Induced Osteomalacia in Global Market
Table 5. Top Tumour-Induced Osteomalacia Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Tumour-Induced Osteomalacia Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Tumour-Induced Osteomalacia Revenue Share by Companies, 2017-2022
Table 8. Global Companies Tumour-Induced Osteomalacia Product Type
Table 9. List of Global Tier 1 Tumour-Induced Osteomalacia Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Tumour-Induced Osteomalacia Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Tumour-Induced Osteomalacia Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Tumour-Induced Osteomalacia Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Tumour-Induced Osteomalacia Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Tumour-Induced Osteomalacia Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Tumour-Induced Osteomalacia Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Tumour-Induced Osteomalacia Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Tumour-Induced Osteomalacia Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Tumour-Induced Osteomalacia Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Tumour-Induced Osteomalacia Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Tumour-Induced Osteomalacia Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Tumour-Induced Osteomalacia Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Tumour-Induced Osteomalacia Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Tumour-Induced Osteomalacia Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Tumour-Induced Osteomalacia Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Tumour-Induced Osteomalacia Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Tumour-Induced Osteomalacia Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Tumour-Induced Osteomalacia Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Tumour-Induced Osteomalacia Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Tumour-Induced Osteomalacia Revenue, (US$, Mn), 2023-2028
Table 30. Kyowa Kirin Corporate Summary
Table 31. Kyowa Kirin Tumour-Induced Osteomalacia Product Offerings
Table 32. Kyowa Kirin Tumour-Induced Osteomalacia Revenue (US$, Mn), (2017-2022)
Table 33. Taizhou Hisound Pharmaceutical Corporate Summary
Table 34. Taizhou Hisound Pharmaceutical Tumour-Induced Osteomalacia Product Offerings
Table 35. Taizhou Hisound Pharmaceutical Tumour-Induced Osteomalacia Revenue (US$, Mn), (2017-2022)
Table 36. Zhejiang Garden Biochemical High-tech Corporate Summary
Table 37. Zhejiang Garden Biochemical High-tech Tumour-Induced Osteomalacia Product Offerings
Table 38. Zhejiang Garden Biochemical High-tech Tumour-Induced Osteomalacia Revenue (US$, Mn), (2017-2022)
Table 39. Kingdomway Nutrition Corporate Summary
Table 40. Kingdomway Nutrition Tumour-Induced Osteomalacia Product Offerings
Table 41. Kingdomway Nutrition Tumour-Induced Osteomalacia Revenue (US$, Mn), (2017-2022)
Table 42. Amgen Corporate Summary
Table 43. Amgen Tumour-Induced Osteomalacia Product Offerings
Table 44. Amgen Tumour-Induced Osteomalacia Revenue (US$, Mn), (2017-2022)
Table 45. Forgo Pharmaceuticals Corporate Summary
Table 46. Forgo Pharmaceuticals Tumour-Induced Osteomalacia Product Offerings
Table 47. Forgo Pharmaceuticals Tumour-Induced Osteomalacia Revenue (US$, Mn), (2017-2022)
Table 48. Abbott Corporate Summary
Table 49. Abbott Tumour-Induced Osteomalacia Product Offerings
Table 50. Abbott Tumour-Induced Osteomalacia Revenue (US$, Mn), (2017-2022)
Table 51. Solvay Corporate Summary
Table 52. Solvay Tumour-Induced Osteomalacia Product Offerings
Table 53. Solvay Tumour-Induced Osteomalacia Revenue (US$, Mn), (2017-2022)
Table 54. GE Healthcare Corporate Summary
Table 55. GE Healthcare Tumour-Induced Osteomalacia Product Offerings
Table 56. GE Healthcare Tumour-Induced Osteomalacia Revenue (US$, Mn), (2017-2022)
Table 57. Siemens Corporate Summary
Table 58. Siemens Tumour-Induced Osteomalacia Product Offerings
Table 59. Siemens Tumour-Induced Osteomalacia Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Tumour-Induced Osteomalacia Segment by Type in 2021
Figure 2. Tumour-Induced Osteomalacia Segment by Application in 2021
Figure 3. Global Tumour-Induced Osteomalacia Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Tumour-Induced Osteomalacia Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Tumour-Induced Osteomalacia Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Tumour-Induced Osteomalacia Revenue in 2021
Figure 8. By Type - Global Tumour-Induced Osteomalacia Revenue Market Share, 2017-2028
Figure 9. By Application - Global Tumour-Induced Osteomalacia Revenue Market Share, 2017-2028
Figure 10. By Region - Global Tumour-Induced Osteomalacia Revenue Market Share, 2017-2028
Figure 11. By Country - North America Tumour-Induced Osteomalacia Revenue Market Share, 2017-2028
Figure 12. US Tumour-Induced Osteomalacia Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Tumour-Induced Osteomalacia Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Tumour-Induced Osteomalacia Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Tumour-Induced Osteomalacia Revenue Market Share, 2017-2028
Figure 16. Germany Tumour-Induced Osteomalacia Revenue, (US$, Mn), 2017-2028
Figure 17. France Tumour-Induced Osteomalacia Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Tumour-Induced Osteomalacia Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Tumour-Induced Osteomalacia Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Tumour-Induced Osteomalacia Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Tumour-Induced Osteomalacia Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Tumour-Induced Osteomalacia Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Tumour-Induced Osteomalacia Revenue Market Share, 2017-2028
Figure 24. China Tumour-Induced Osteomalacia Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Tumour-Induced Osteomalacia Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Tumour-Induced Osteomalacia Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Tumour-Induced Osteomalacia Revenue, (US$, Mn), 2017-2028
Figure 28. India Tumour-Induced Osteomalacia Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Tumour-Induced Osteomalacia Revenue Market Share, 2017-2028
Figure 30. Brazil Tumour-Induced Osteomalacia Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Tumour-Induced Osteomalacia Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Tumour-Induced Osteomalacia Revenue Market Share, 2017-2028
Figure 33. Turkey Tumour-Induced Osteomalacia Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Tumour-Induced Osteomalacia Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Tumour-Induced Osteomalacia Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Tumour-Induced Osteomalacia Revenue, (US$, Mn), 2017-2028
Figure 37. Kyowa Kirin Tumour-Induced Osteomalacia Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Taizhou Hisound Pharmaceutical Tumour-Induced Osteomalacia Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Zhejiang Garden Biochemical High-tech Tumour-Induced Osteomalacia Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Kingdomway Nutrition Tumour-Induced Osteomalacia Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Amgen Tumour-Induced Osteomalacia Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Forgo Pharmaceuticals Tumour-Induced Osteomalacia Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Abbott Tumour-Induced Osteomalacia Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Solvay Tumour-Induced Osteomalacia Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. GE Healthcare Tumour-Induced Osteomalacia Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Siemens Tumour-Induced Osteomalacia Revenue Year Over Year Growth (US$, Mn) & (2017-2022)